Pfizer Inc. and its subsidiary companies disclose their financial performance over a three and nine-month period, ending October 3, 2021. The reports encompass revenues, costs, expenses, net income, earnings per share, as well as the company's balance sheet detailing assets, liabilities, and equity. The statements further elaborate on comprehensive income, equity, common and preferred stock, treasury stock, retained earnings, and comprehensive income allocation to noncontrolling interests. Additionally, the company presents information on financial instruments, including fair value measurements of assets and liabilities, investments, short-term borrowings, long-term debt, and derivative instruments used for hedging activities. This includes insights into various types of investments, such as equity securities, available-for-sale debt securities, held-to-maturity debt securities, and private equity securities, alongside details on derivative assets and liabilities related to interest rate and foreign exchange contracts and the company's risk management strategies using derivative financial instruments.
Pfizer, a biopharmaceutical company, has seen revenue growth in 2021 through various strategic transformations and collaborations, such as forming a Consumer Healthcare joint venture and spinning off its Upjohn Business. The company has engaged in partnerships with Biohaven, Altaris Capital Partners, and others in research and development projects while noting operational challenges like regulatory environments and COVID-19 impacts. Financially, Pfizer discusses costs, expenses, and Adjusted Income, a non-GAAP measure used to evaluate its performance, which excludes significant items and provides reconciliations to GAAP figures.
The text states that information regarding quantitative and qualitative disclosures about market risk is incorporated by reference from the Analysis of Financial Condition, Liquidity, Capital Resources, and Market Risk section within the Management's Discussion and Analysis (MD&A) of the company's 2020 Form 10-K.
The text discusses the evaluation of the effectiveness of disclosure controls and procedures conducted by the principal executive officer and principal financial officer at the end of the reporting period. They concluded that the controls and procedures are effective in timely alerting them to material information required for disclosure in periodic reports filed with the SEC. Additionally, there have been no significant changes in internal control over financial reporting during the most recent fiscal quarter.
The text provided is mentioning that certain legal proceedings involving the entity are discussed in Note 12A.
The text provided references specific sections of a Form 10-Q and a previous 10-K filing related to risk factors, including the operating environment, global economic conditions, COVID-19 pandemic impact, and factors affecting future results.
The text provided details unregistered sales of equity securities and the use of proceeds during the third quarter of 2021, summarizing purchases of common stock made by the company. It includes information on the total number of shares purchased, average prices paid per share, and the approximate value of shares yet to be purchased under the plan. Additionally, it contains information on shares surrendered to the company to satisfy tax withholding obligations and open market purchases by a trustee for employees' deferred performance awards. The text also mentions various exhibits related to certifications by the Chief Executive Officer and Chief Financial Officer pursuant to the Sarbanes-Oxley Act of 2002. Lastly, the document is signed by Pfizer Inc.'s Senior Vice President and Controller on November 12, 2021.
The text provided is incomplete and does not provide enough context to summarize accurately.
The text provided is a statement indicating that there are no disclosures related to mine safety in the context it was given.
The text does not provide any additional information or context in Item 5.
The text provides a list of exhibits included in a report, such as certifications by the Chief Executive Officer and Chief Financial Officer pursuant to certain sections of the Sarbanes-Oxley Act of 2002. It also includes various documents related to Inline XBRL Taxonomy Extension and states that the report has been signed by Jennifer B. Damico, the Senior Vice President and Controller of Pfizer Inc.
